TOMM20是脊索瘤中潜在的预后生物标志物：来自一批，单中心研究的结果
TOMM20 as a Potential Prognostic Biomarker in Chordoma: Results From a High-Volume, Single-Center Study
影响因子:1.90000
分区:医学4区 / 病理学3区
发表日期:2023 May 02
作者:
Ida Micaily, Sherry Lee, Atrayee Basu Mallick, Tingting Zhan, Raymond O'Neill, Stacey Gargano, Bryan Hozack, Sameep Thapa, Ubaldo Martinez-Outschoorn, John Abraham, Wei Jiang
摘要
由于很少有大型研究鉴定了脊索瘤中的相关生物标志物，因此我们的目标是使用我们的大型单中心脊髓瘤肿瘤库来鉴定新的信号通路。对73例脊髓瘤患者的临床和病理数据进行了回顾性收集。肿瘤微阵列是由61个存档的弦瘤标本建造的；进行了Tomm20，Tigar和MCT1的免疫组织化学；对阳性肿瘤细胞的染色强度和百分比进行了半定量分析。通过疾病状态和解剖位置比较了MCT1，Tigar和Tomm20表达的平均综合评分。与原发性病变相比，在复发和转移性脊髓瘤中观察到Tomm20的高表达。比较原发性疾病患者的原发性病变的复合评分与复发性疾病的患者的比较表明，原发性病变中Tigar和Tomm20表达式明显更高，随后是复发史。 TOMM20复合评分大于或等于3显着降低总体存活率（危险比[HR]，5.83）和无复发生存率（HR，8.95）。识别促进脊索瘤生长和复发的新型信号通路对于为脊索瘤开发目标治疗至关重要。 TOMM20可能是与核瘤疾病进展相关的生物标志物。
Abstract
As few large studies identify correlative biomarkers in chordoma, our objective was to use our large, single-center chordoma tumor bank to identify novel signaling pathways.Clinical and pathologic data for 73 patients with chordoma were retrospectively collected. Tumor microarrays were built from 61 archived chordoma specimens; immunohistochemistry for TOMM20, TIGAR, and MCT1 were performed; and semiquantitative analysis of staining intensity and percentage of positive tumor cells was performed. Average composite scores of MCT1, TIGAR, and TOMM20 expression were compared by disease status and anatomic location.Higher expression of TOMM20 was seen in recurrent and metastatic chordomas compared with primary lesions. Comparing composite scores of primary lesions in patients with primary disease only vs those with recurrent disease showed that TIGAR and TOMM20 expressions are significantly higher in primary lesions, followed by a history of recurrence. A TOMM20 composite score of greater than or equal to 3 significantly decreased overall survival (hazard ratio [HR], 5.83) and recurrence-free survival (HR, 8.95).Identifying novel signaling pathways that promote chordoma growth and recurrence is critical for developing targeted therapy for chordoma. TOMM20 may be a biomarker associated with chordoma disease progression.